董事长专访 | 睿智医药胡瑞连：三重战略推动企业逆风翻盘

Core Insights - The chairman of Ruizhi Pharmaceutical, Hu Ruilian, emphasizes the importance of finding a unique path in a competitive market, particularly during a price war in the CXO industry [3][4] - Under Hu's leadership, the company achieved a revenue of 534 million yuan, a year-on-year increase of 14.75%, and a net profit of 25.38 million yuan, marking a successful turnaround [3][4] - The company is focusing on a systematic strategic layout, including comprehensive service offerings, technological innovation, and global expansion [3][4] Financial Performance - In the first half of 2025, Ruizhi Pharmaceutical reported a revenue of 534 million yuan, reflecting a 14.75% year-on-year growth [3] - The company achieved a net profit of 25.38 million yuan, successfully reversing previous losses [3] Strategic Transformation - Hu Ruilian initiated a transformation from a fragmented subcontracting model to a one-stop delivery service model, enhancing efficiency and customer satisfaction [4][5] - The new service model allows clients to specify their needs while the company manages the entire process, creating a competitive barrier in the market [5] Technological Innovation - The company has made significant advancements in technology, particularly with the launch of the micro-flow manufacturing system in collaboration with East China Normal University [6][7] - This system is expected to revolutionize drug manufacturing by significantly reducing production space and time, while also lowering costs and impurities [6][7] Market Expansion - Ruizhi Pharmaceutical is establishing a biopharmaceutical industrial park in Malaysia, which aims to serve as a bridge for Chinese pharmaceutical companies entering the ASEAN market [8] - The park is strategically positioned to access a large market of approximately 2 billion Muslims, leveraging Malaysia's authoritative halal certification [8] Global Strategy - The company has developed a clear global layout, combining a Shanghai R&D base, localized operations in Europe and the U.S., and the Malaysian industrial park to serve emerging markets [9] - This diversified approach allows Ruizhi Pharmaceutical to support both domestic biotech companies and international pharmaceutical firms [9]